Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Stock Price & Analysis
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — MoonshotScore 49/100 (Fair band), calculated Nov 18, 2026. Price $10.26 (+0.29%), as of the Nov 19, 2026 trading session; market cap $654M.
Educational signal · not a buy or sell recommendation · How to read this
Drugs Made In America Acquisition II Corp. Ordinary Shares · DMII · NASDAQ
Drugs Made In America Acquisition II Corp. is a shell company focused on identifying and merging with a private business. The company aims to create value through a business combination, but currently has no significant operations.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strained balance sheet, weak growth and an expensive valuation, though quality is only middling. Business Quality: Average; Financial Safety: Strained; Valuation: Rich; Growth Durability: Fading; Momentum: Rising.
- Altman Z 21.52 · Piotroski F 2
Holding back: a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 55 | Fair | |
| 55 | Fair | |
| 55 | Fair | |
| 55 | Fair | |
| 49 | Fair | |
| 49 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.26 | |
| Change on the day | +0.29% | |
| 52-week range | $9.86 – $10.33 | |
| Market capitalisation | $654M | — |
| Price / earnings (trailing) | 26.27 | |
| Shares traded on the day | 27.9K |
Price & events
Other perspectives
Council score for Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) is listed on NASDAQ. It employs 2 people and is led by Roger Bendelac. The market values it at $654M.
What are the financial strengths and risks for Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII)?
Short answer · as of
What is holding it back is a rich price, soft growth. The distress and quality screens read Altman Z 21.52 · Piotroski F 2. Trailing ratios: current ratio 0.22.
How does Drugs Made In America Acquisition II Corp. Ordinary Shares compare with its peers?
Short answer
Drugs Made In America Acquisition II Corp. Ordinary Shares's score ranks tied for 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $10.09 Nov 18, 2026 | $437M | 66 5-pillar Nov 18, 2026 | |
| $10.11 Nov 18, 2026 | $310M | 65 5-pillar Nov 18, 2026 | |
| $10.15 Nov 18, 2026 | $233M | 65 5-pillar Nov 18, 2026 | |
| $3.03 Nov 18, 2026 | $122M | 56 5-pillar Nov 18, 2026 | |
| $10.13 Nov 18, 2026 | $291M | 52 5-pillar Nov 18, 2026 | |
| $10.04 Nov 18, 2026 | $500M | 51 5-pillar Nov 18, 2026 | |
| $10.11 Nov 18, 2026 | $344M | 51 5-pillar Nov 18, 2026 | |
| $10.16 Nov 18, 2026 | $234M | 51 5-pillar Nov 18, 2026 | |
| $10.53 Nov 18, 2026 | $105M | 51 5-pillar Nov 18, 2026 | |
| $36.44 Nov 18, 2026 | $512M | 50 5-pillar Nov 18, 2026 | |
| $10.14 Nov 18, 2026 | $476M | 50 5-pillar Nov 18, 2026 | |
| Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — this page | $10.26 | $654M | 49 |
| $10.14 Nov 18, 2026 | $318M | 49 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 6
- Purchases
- 4
- Sales
- 2
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held DMII in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported DMII in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII)
These answers are editorial: 2 of these 9 answers are drawn from the DMII research dossier (written May 9, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for DMII?
DMII carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is DMII a good stock to buy?
Stock Expert AI does not rate DMII buy, sell or hold. Drugs Made In America Acquisition II Corp. Ordinary Shares carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the DMII stock price today?
The last price recorded for Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Drugs Made In America Acquisition II Corp. Ordinary Shares do?
Drugs Made In America Acquisition II Corp. (DMII) operates as a special purpose acquisition company (SPAC). Its core function is to raise capital through an initial public offering (IPO) with the explicit intention of merging with or acquiring a private company. DMII does not have any independent business operations of its own.
What are the main risks for DMII?
Drugs Made In America Acquisition II Corp. (DMII) faces several key risks inherent to its nature as a special purpose acquisition company (SPAC).
What are the key factors to evaluate for DMII?
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does DMII data refresh on this page?
DMII's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven DMII's recent stock price performance?
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Experienced management team with a track record in SPAC transactions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DMII overvalued or undervalued right now?
The trailing P/E of Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com